Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,368 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder OR higher carbohydrate Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

NCT03984448
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
634
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03034915
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS, Placebo via ELLIPTA, Placebo via DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
2,696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

NCT00004907
View directory record Official record
Conditions
Lymphoma
Interventions
busulfan, cyclophosphamide, etoposide, allogeneic bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
15 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition Intervention to Promote Immune Recovery From Sleep Restriction

NCT03525184
View directory record Official record
Conditions
Sleep Restriction
Interventions
Additional protein and multi-nutrient beverage, Placebo beverage
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

NVA237 Versus Placebo 12-week Efficacy Study

NCT01709864
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
NVA237, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
54
States / cities
Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 4 Interventional

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

NCT00106821
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide Inhalation Powder
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Sepulveda, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 13, 2026, 11:24 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma

NCT07665892
View directory record Official record
Conditions
Safety in Asthma Patients
Interventions
ASY202, Placebo
Combination Product
Lead sponsor
Aspeya, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Glendale, Arizona • Anaheim, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 13, 2026, 11:24 PM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine Plus Ascorbate for Sarcoma in Adults

NCT03468075
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
Interventions
Ascorbate, Gemcitabine
Drug
Lead sponsor
Mohammed Milhem, MBBS
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 13, 2026, 11:24 PM EDT
Recruiting Not applicable Interventional

Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults

NCT06025292
View directory record Official record
Conditions
Hyperglycaemia (Non Diabetic), Prediabetes
Interventions
Lean Pork vs Plant-Based Protein
Other
Lead sponsor
University of Arkansas
Other
Eligibility
40 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer

NCT00001498
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
methotrexate, leucovorin, 5-fluorouracil, cyclophosphamide, peripheral blood progenitor cell, paclitaxel, doxorubicin
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 13, 2026, 11:24 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT05650112
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
FB-001, Placebo
Biological
Lead sponsor
Federation Bio Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

NCT00195000
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Mylotarg, Cytarabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

NCT00002630
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, cyclophosphamide, melphalan, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Not applicable Interventional

The Effects of Nutrition Supplementation and Education on the Healing of Diabetic Foot Ulcer (DFU)

NCT04055064
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
glucose control nutritional shake, nutrition education
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
30 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

NCT00554372
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Genetic
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
5
States / cities
La Jolla, California • Rochester, Minnesota • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

NCT03346057
View directory record Official record
Conditions
Reversal of Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 4 Interventional Results available

Muscle Relaxation for Pediatric Adenotonsillectomy

NCT06225466
View directory record Official record
Conditions
Tonsillectomy
Interventions
Rocuronium, Sugammadex, Anesthesia without neuromuscular blockade
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
2 Years to 12 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Phase 2 Interventional

DMT310-001 Topical in the Treatment of Acne Vulgaris

NCT03536637
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Hydrogen Peroxide, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
San Diego, California • Saint Joseph, Missouri • Henderson, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 13, 2026, 11:24 PM EDT
Not yet recruiting Phase 2 Interventional

A Multicenter, Prospective, Randomized, Placebo and Non-Surgical Standard of Care (NSSOC) Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to NSSOC in Participants With Venous Leg Ulcers (VLU)

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC)
Drug · Other
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Maimi, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 13, 2026, 11:24 PM EDT
Withdrawn Phase 2 Interventional

Vitamin C for Severe Thermal Injuries

NCT01587261
View directory record Official record
Conditions
Severe Thermal Injury, Greater Than 20% TBSA
Interventions
Vitamin C, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Role of Altered Nutrient Partitioning in Food Reward

NCT05200845
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Conditioned Stimulus + (CS+): Flavored beverage solution with 75 calories of sucrose, Conditioned Stimulus - (CS-): Flavored beverage solution with sweetness-matched sucralose, High-Fat Test Meal Inside a Metabolic Chamber, High-Carbohydrate Test Meal Inside a Metabolic Chamber, fMRI Scan
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 13, 2026, 11:24 PM EDT
Completed Not applicable Interventional

Role of Macronutrient Diet Composition and Infant Metabolic Outcomes in Gestational Diabetes

NCT01719029
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Low-Carbohydrate/Higher Fat Diet, High Carbohydrate/Low fat diet
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 13, 2026, 11:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Spirulina Supplementation on Mental Health in Healthy Adults

NCT06936202
View directory record Official record
Conditions
Depression, Mental Acuity
Interventions
Spirulina capsules, Placebo
Other
Lead sponsor
Arizona State University
Other
Eligibility
16 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 13, 2026, 11:24 PM EDT